Literature DB >> 16816364

Overexpression of the transcription factor GATA-3 enhances the development of pulmonary fibrosis.

Toru Kimura1, Yukio Ishii, Keigyou Yoh, Yuko Morishima, Takashi Iizuka, Takumi Kiwamoto, Yosuke Matsuno, Shinsuke Homma, Akihiro Nomura, Tohru Sakamoto, Satoru Takahashi, Kiyohisa Sekizawa.   

Abstract

Recent studies have demonstrated that Th2 cytokines, such as interleukin-4 and interleukin-13, enhance fibrotic processes by activating fibroblast proliferation and collagen production, whereas interferon-gamma, a Th1 cytokine, inhibits these processes. Th1 and Th2 cells both differentiate from common T precursor cells, with transcription factor GATA-3 a key regulator of Th2 differentiation. In the present study, therefore, we examined the effects of GATA-3 overexpression on the development of pulmonary fibrosis in a mouse model. Wild-type C57BL/6 mice and GATA-3-overexpressing (GATA-3-tg) mice of the same background were intratracheally treated with bleomycin. The survival rate after bleomycin was significantly decreased in GATA-3-tg mice compared with wild-type mice. The degree of pulmonary fibrosis was much greater in GATA-3-tg mice than in wild-type mice 28 days after bleomycin treatment. Lung interferon-gamma concentration was significantly decreased in GATA-3-tg mice compared with wild-type mice by 7 days after either saline or bleomycin treatment. The concentration of transforming growth factor-beta, a fibrogenic cytokine, was significantly higher in GATA-3-tg mice than in wild-type mice. Exogenous administration of interferon-gamma to GATA-3-tg mice improved the degree of pulmonary fibrosis and thus increased survival. These results indicate that overexpression of GATA-3 enhances the development of pulmonary fibrosis, possibly by reducing interferon-gamma levels in the lung.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16816364      PMCID: PMC1698754          DOI: 10.2353/ajpath.2006.051160

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  51 in total

Review 1.  NHLBI Workshop Summary. Pharmacological therapy for idiopathic pulmonary fibrosis. Past, present, and future.

Authors:  R J Mason; M I Schwarz; G W Hunninghake; R A Musson
Journal:  Am J Respir Crit Care Med       Date:  1999-11       Impact factor: 21.405

2.  GATA-3 suppresses IFN-gamma promoter activity independently of binding to cis-regulatory elements.

Authors:  Osamu Kaminuma; Fujiko Kitamura; Noriko Kitamura; Makoto Miyagishi; Kazunari Taira; Koh Yamamoto; Osamu Miura; Shoichiro Miyatake
Journal:  FEBS Lett       Date:  2004-07-16       Impact factor: 4.124

3.  Simple method of estimating severity of pulmonary fibrosis on a numerical scale.

Authors:  T Ashcroft; J M Simpson; V Timbrell
Journal:  J Clin Pathol       Date:  1988-04       Impact factor: 3.411

4.  Effect of murine gamma interferon on the cellular responses to bleomycin in mice.

Authors:  D M Hyde; T S Henderson; S N Giri; N K Tyler; M Y Stovall
Journal:  Exp Lung Res       Date:  1988       Impact factor: 2.459

5.  Morphometric estimates of infiltrative cellular changes during the development of bleomycin-induced pulmonary fibrosis in hamsters.

Authors:  D B Chandler; D M Hyde; S N Giri
Journal:  Am J Pathol       Date:  1983-08       Impact factor: 4.307

6.  Bleomycin-induced interstitial pulmonary disease in the nude, athymic mouse.

Authors:  S V Szapiel; N A Elson; J D Fulmer; G W Hunninghake; R G Crystal
Journal:  Am Rev Respir Dis       Date:  1979-10

7.  A comparison of lymphocyte populations in lung tissue and in bronchoalveolar lavage fluid of rats at various times during the development of bleomycin-induced pulmonary fibrosis.

Authors:  R S Thrall; R W Barton
Journal:  Am Rev Respir Dis       Date:  1984-02

8.  The effects of the nude (nu/nu) mutation on bleomycin-induced pulmonary fibrosis. A biochemical evaluation.

Authors:  D J Schrier; S H Phan; B M McGarry
Journal:  Am Rev Respir Dis       Date:  1983-05

9.  The pathogenesis of bleomycin-induced pulmonary fibrosis in mice.

Authors:  I Y Adamson; D H Bowden
Journal:  Am J Pathol       Date:  1974-11       Impact factor: 4.307

10.  Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis.

Authors:  P F Piguet; M A Collart; G E Grau; Y Kapanci; P Vassalli
Journal:  J Exp Med       Date:  1989-09-01       Impact factor: 14.307

View more
  18 in total

1.  Cytokine-like factor 1 gene expression is enriched in idiopathic pulmonary fibrosis and drives the accumulation of CD4+ T cells in murine lungs: evidence for an antifibrotic role in bleomycin injury.

Authors:  Daniel J Kass; Guoying Yu; Katrina S Loh; Asaf Savir; Alain Borczuk; Rehan Kahloon; Brenda Juan-Guardela; Giuseppe Deiuliis; John Tedrow; Jiin Choi; Thomas Richards; Naftali Kaminski; Steven M Greenberg
Journal:  Am J Pathol       Date:  2012-03-16       Impact factor: 4.307

2.  Different profiles of notch signaling in cigarette smoke-induced pulmonary emphysema and bleomycin-induced pulmonary fibrosis.

Authors:  Shi Li; Xiaofei Hu; Zheng Wang; Meng Wu; Jinnong Zhang
Journal:  Inflamm Res       Date:  2015-03-27       Impact factor: 4.575

3.  Pulmonary vaccination as a novel treatment for lung fibrosis.

Authors:  Samuel L Collins; Yee Chan-Li; Robert W Hallowell; Jonathan D Powell; Maureen R Horton
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

4.  Transcription factor ets-2 plays an important role in the pathogenesis of pulmonary fibrosis.

Authors:  Christopher P Baran; Sara N Fischer; Gerard J Nuovo; Mohamed N Kabbout; Charles L Hitchcock; Benjamin D Bringardner; Sara McMaken; Christie A Newland; Carmen Z Cantemir-Stone; Gary S Phillips; Michael C Ostrowski; Clay B Marsh
Journal:  Am J Respir Cell Mol Biol       Date:  2011-05-11       Impact factor: 6.914

5.  γδ T cells attenuate bleomycin-induced fibrosis through the production of CXCL10.

Authors:  Derek A Pociask; Kong Chen; Sun Mi Choi; Tim D Oury; Chad Steele; Jay K Kolls
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

6.  Nrf2 protects against pulmonary fibrosis by regulating the lung oxidant level and Th1/Th2 balance.

Authors:  Norihiro Kikuchi; Yukio Ishii; Yuko Morishima; Yuichi Yageta; Norihiro Haraguchi; Ken Itoh; Masayuki Yamamoto; Nobuyuki Hizawa
Journal:  Respir Res       Date:  2010-03-18

7.  Th2-biased GATA-3 transgenic mice developed severe experimental peritoneal fibrosis compared with Th1-biased T-bet and Th17-biased RORγt transgenic mice.

Authors:  Keigyou Yoh; Masami Ojima; Satoru Takahashi
Journal:  Exp Anim       Date:  2015-07-06

8.  T-bet, but not Gata3, overexpression is detrimental in a neurotropic viral infection.

Authors:  Fumitaka Sato; Eiichiro Kawai; Nicholas E Martinez; Seiichi Omura; Ah-Mee Park; Satoru Takahashi; Keigyou Yoh; Ikuo Tsunoda
Journal:  Sci Rep       Date:  2017-09-05       Impact factor: 4.379

9.  Overexpression of transforming growth factor-beta 1 in the valvular fibrosis of chronic rheumatic heart disease.

Authors:  Lucia Kim; Do Kyun Kim; Woo Ick Yang; Dong Hwan Shin; Ick Mo Jung; Han Ki Park; Byung Chul Chang
Journal:  J Korean Med Sci       Date:  2008-02       Impact factor: 2.153

10.  Regulation of an autoimmune model for multiple sclerosis in Th2-biased GATA3 transgenic mice.

Authors:  Viromi Fernando; Seiichi Omura; Fumitaka Sato; Eiichiro Kawai; Nicholas E Martinez; Sadie Faith Elliott; Keigyou Yoh; Satoru Takahashi; Ikuo Tsunoda
Journal:  Int J Mol Sci       Date:  2014-01-23       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.